UK-based Bicycle Therapeutics Ltd has hired Peter Park from Mersana Therapeutics Inc to head its oncology research unit in the company’s US office in Cambridge, Massachusetts. Bicycle is developing a type of peptide therapeutic to treat cancer including drug conjugates. Dr Park has antibody-drug conjugate experience from both Mersana and ImmunoGen Inc. He received his bachelor of science degree and PhD in biology from the Massachusetts Institute of Technology.
Bicycle Therapeutics announced the appointment on 11 October 2016.
Copyright 2016 Evernow Publishing Ltd